Research and Markets (http://www.researchandmarkets.com/research/j84hq9/chemotherapy) has announced the addition of the "Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015" report to their offering.

The report, Chemotherapy Induced Neutropenia - Pipeline Review, H2 2015, provides an overview of the Chemotherapy Induced Neutropenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Key Topics Covered:

  • Snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia
  • Key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • Key players involved in the therapeutics development for Chemotherapy Induced Neutropenia and enlists all their major and minor projects
  • All dormant and discontinued pipeline projects
  • Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • Detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Benefits of this Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • Apotex, Inc.
  • Biogenomics Limited
  • Bolder Biotechnology, Inc.
  • Cellerant Therapeutics, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dr. Reddy's Laboratories Limited
  • Generon (Shanghai) Corporation Ltd.
  • Genexine, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Hospira, Inc.
  • Myelo Therapeutics GmbH
  • Octapharma AG
  • Pfenex Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Reliance Life Sciences Pvt. Ltd.
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • UAB Profarma
  • USV Limited
  • Welichem Biotech Inc.

For more information visit http://www.researchandmarkets.com/research/j84hq9/chemotherapy

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: Oncology